Generationof Aβ from the APP was thought to be central in the pathogenesisof Alzheimer’s disease.2 In thisproteolytic cascade, the β-secretase BACE1 is the rate-limitingenzyme.49 Many efforts have been undertakento develop and explore BACE1 inhibitors in a clinical setting to alleviatethe burden of the disease. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.